Orexigen to resubmit US NDA for obesity drug Contrave

26 November 2013

Along with presenting new data for its weight loss drug candidate Contrave (naltrexone SR and bupropion SR), US biopharma firm Orexigen Therapeutics (Nasdaq: OREX) said it plans to resubmit the New Drug Application for the drug to the US Food and Drug Administration in the next few weeks with potential approval by June 2014.

Orexigen’s shares rose 11.8% to $6.35 in morning trading on Monday (November 25), having risen as much as 22% in pre-market activity.

The company recently resubmitted its European Marketing Applications for Contrave, which is under development with Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502; The Pharma Letter October 4).The MMA is for the management of obesity, including weight loss and maintenance of weight loss.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK